Pernix Therapeutics Holdings, Inc.
10003 Woodloch Forest Drive, Suite 950
The Woodlands, TX 77380
tel: (800) 793-2145
fax: (832) 934-1857
company website
10003 Woodloch Forest Drive, Suite 950
The Woodlands, TX 77380
tel: (800) 793-2145
fax: (832) 934-1857
company website
Pernix Therapeutics
Improving Health and Well-Being
Pernix Therapeutics, founded in 1996 and headquartered in The Woodlands, is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic and over-the-counter (OTC) pharmaceutical products. In 2011, Pernix’s revenues increased 82% to approximately $61 million primarily due to the launch of new branded and generic products. Also, a product candidate utilizing cough-related intellectual property is in development and expected to be introduced to the U.S. OTC market.
Pernix manages a portfolio of branded and generic products. The company’s branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections; NATROBA™, a topical treatment for head lice; and a family of treatments for cough and cold (BROVEX®, ALDEX® and PEDIATEX®). The company’s branded products for gastroenterology include OMECLAMOX-PAK®; a 10-day treatment for H.Pylori infection and duodenal ulcer disease; and REZYST™, a probiotic blend to promote dietary management. The company promotes its branded pediatric and gastroenterology products through its sales force.
Pernix markets its generic products through its wholly owned subsidiary, Macoven Pharmaceuticals. Macoven provides affordable, high-quality products in the areas of cough, cold, pain, antibiotic, dermatology, vitamins, gastroenterology and head lice.
Sales of generic products represented 32% of the company’s total revenues in 2011.
In July 2012, Pernix acquired Great Southern Labs, which was established in 1980 and is located in Houston. Great Southern Labs manufactures and packages products for the pharmaceutical industry in a wide range of dosage forms.
For more information about Pernix, please visit the company’s website at www.pernixtx.com.
Improving Health and Well-Being
Pernix Therapeutics, founded in 1996 and headquartered in The Woodlands, is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic and over-the-counter (OTC) pharmaceutical products. In 2011, Pernix’s revenues increased 82% to approximately $61 million primarily due to the launch of new branded and generic products. Also, a product candidate utilizing cough-related intellectual property is in development and expected to be introduced to the U.S. OTC market.
Pernix manages a portfolio of branded and generic products. The company’s branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections; NATROBA™, a topical treatment for head lice; and a family of treatments for cough and cold (BROVEX®, ALDEX® and PEDIATEX®). The company’s branded products for gastroenterology include OMECLAMOX-PAK®; a 10-day treatment for H.Pylori infection and duodenal ulcer disease; and REZYST™, a probiotic blend to promote dietary management. The company promotes its branded pediatric and gastroenterology products through its sales force.
Pernix markets its generic products through its wholly owned subsidiary, Macoven Pharmaceuticals. Macoven provides affordable, high-quality products in the areas of cough, cold, pain, antibiotic, dermatology, vitamins, gastroenterology and head lice.
Sales of generic products represented 32% of the company’s total revenues in 2011.
In July 2012, Pernix acquired Great Southern Labs, which was established in 1980 and is located in Houston. Great Southern Labs manufactures and packages products for the pharmaceutical industry in a wide range of dosage forms.
For more information about Pernix, please visit the company’s website at www.pernixtx.com.